 Company recently earned a 25 million milestone payment as NIS793 advanced to Phase 2 development in advanced pancreatic cancer An u ndisclosed partner entered Phase 2 development, triggering a 0.5 million milestone Rezolutes financing resulted in accelerated 1.4 million payment Two partners presented early stage data at scientific conferences Acquired royalty interest in four lysosomal storage disorder enzymes being developed by Chiesi Group Additional partner-funded assets advanced to next stages of clinical development, even though clinical trial enrollment across the industry remains challenging due to the COVID-19 pandemic 